Dr. Mucke is an accomplished scientist, science author, patent analyst and R&D manager who had a strong role in the repurposing of several drugs, including galantamine for Alzheimer’s disease. He also helped to take a pharmaceutical company public on the Frankfurt Stock Exchange in 1999. Dr. Mucke serves on several corporate scientific advisory boards and is an editorial board member and regular author of several scientific journals, such as the Pharmaceutical Patent Analyst. Among many other market and technology analyses, Dr. Mucke is the author of “Drug Repositioning: Extracting added value from prior R&D investments”, published by Insight Pharma Reports). He is founder of HM Pharma Consultancy, and undertakes corporate scientific & IP management of several pharmaceutical companies.